Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06415110

A Prospective Analysis of the Efficacy of Allosync Expand and Autograft Bone Graft in Open Lumbar Spinal Fusion

The purpose of this study is to assess the radiographic and clinical outcomes of spinal fusion following use of Allosync Expand and autograft bone graft.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

About this study

This is a single site, prospective study with patients selected as study subjects from the Investigator's standard patient population who fulfill the Inclusion/Exclusion Criteria and agree to participate in the study. The study surgery is standard of care, with patients identified as requiring surgery prior to enrollment. The study surgery is lumbar posterior fixation with supplemental posterolateral fusion at from 1 to 3 levels. One side of the posterolateral fusion will be Allosync Expand (utilizing the BMA Angel kit to hydrate) and the other side to autograft bone (control).

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 22years of age at the time of consent
  • Subject must have a documented diagnosis of spondylolisthesis up to Grade I. and have confirmed back and/or radicular pain with associated spinal stenosis as documented by conditions such as:
  • Instability as defined by >3mm translation or >5 degree angulation
  • Osteophyte formation of facet joints or vertebral endplates
  • Subject presents with one or more of the following:
  • Radiculopathy
  • Sensory deficit
  • Motor weakness
  • Reflex changes
  • Subject requires lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1).
  • The number of levels decompressed must equal the number of levels fused.
  • Subject must have been unresponsive to conservative care for at least 3 months prior to fusion surgery.
  • Subject must be willing and able to sign an informed consent document.
  • Subject must be willing and able to return for all follow-up visits, agree to participate in postoperative clinical and radiographic evaluations and comply with the required study regimen.

Exclusion criteria

  • Subject has had prior lumbar spine fusion surgery at any level.
  • Subject has greater than grade 1 spondylolisthesis of the lumbar spine.
  • Subject is pregnant or nursing or planning to become pregnant during the two years (24 months) following arthrodesis
  • Subject has an active local or systemic infection.
  • Subject is a prisoner
  • Patient has any condition (including malignancy), that in the opinion of the Investigator, would prohibit the patient from complying with and/or completing the protocol

Treatment and study plan

Allosync Expand

Device

Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)

Other names: Acceell Family of Products (Accell DBM 100, Accell TBM, A2i, and Accell Connexus)

Primary outcomes

  1. Lumbar fusion rate assessed via CT

    Time frame: 12 months post surgery

    Lumbar fusion rate assessed via CT at 12 months post surgery

Secondary outcomes

  1. Clinical outcome via neck visual analog scale (VAS)

    Time frame: 12 months post surgery

    Standard of care patient reported neck visual analog scale (VAS) will be used to evaluate patient pain. On a scale of 0 to 10 with a score of 0 being no pain and a score of 10 being worst pain. A low score means a better clinical outcome. A high score means a worse clinical outcome.

  2. Clinical outcome via Overall Quality of Life (EQ-5D) EuroQol Research Foundation

    Time frame: 12 months post surgery

    Standard of care patient reported Overall Quality of Life (EQ-5D) EuroQol Research Foundation will be used to evaluate patient quality of life. On a scale of 3 levels: no problems, some problems, and extreme problems. With a score of "no problems" being no interference in quality of life and a score of "extreme problems" being a high interference in quality of life. "No problems" responses means a better clinical outcome. "Extreme problems" responses mean a worse clinical outcome.

  3. Clinical outcome via PROMIS short form - Physical Evaluation

    Time frame: 12 months post surgery

    Standard of care patient reported PROMIS short form - Physical Evaluation will be used to evaluate patient physical function. On a scale of 5 levels: without any difficulty, with a little difficulty, with some difficulty, with much difficulty, and unable to do. With a score of "without any difficulty" being no interference in physical function and a score of "unable to do" being high interference in physical function. "Without any difficulty" means a better clinical outcome. "Unable to do" means a worse clinical outcome.

Sponsors and collaborators

Lead sponsor

Research Source

Network

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
May 16, 2024
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.